OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019
Yiyi Yao, Xiangjie Lin, Fenglin Li, et al.
BioMedical Engineering OnLine (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 59
Yiyi Yao, Xiangjie Lin, Fenglin Li, et al.
BioMedical Engineering OnLine (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 59
Showing 1-25 of 59 citing articles:
Chronic lymphocytic leukaemia
Nitin Jain, William G. Wierda, Susan O’Brien
The Lancet (2024) Vol. 404, Iss. 10453, pp. 694-706
Closed Access | Times Cited: 16
Nitin Jain, William G. Wierda, Susan O’Brien
The Lancet (2024) Vol. 404, Iss. 10453, pp. 694-706
Closed Access | Times Cited: 16
Quality by design endorsed fabrication of Ibrutinib-loaded human serum albumin nanoparticles for the management of leukemia
Paras Famta, Saurabh Shah, Ganesh Vambhurkar, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2023) Vol. 190, pp. 94-106
Closed Access | Times Cited: 20
Paras Famta, Saurabh Shah, Ganesh Vambhurkar, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2023) Vol. 190, pp. 94-106
Closed Access | Times Cited: 20
In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia
Suliman A. Alsagaby, Danish Iqbal, Iqrar Ahmad, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 25
Suliman A. Alsagaby, Danish Iqbal, Iqrar Ahmad, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 25
Multiple omics levels of chronic lymphocytic leukemia
Aleksander Turk, Eva Čeh, George A. Călin, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 5
Aleksander Turk, Eva Čeh, George A. Călin, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 5
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
Rong Dong, Youyou Yan, Xiaokang Zeng, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3225-3239
Open Access | Times Cited: 19
Rong Dong, Youyou Yan, Xiaokang Zeng, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3225-3239
Open Access | Times Cited: 19
Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer.
Madison T. Hindes, Anthony M. McElligott, Giles Best, et al.
Cancer Letters (2025), pp. 217441-217441
Closed Access
Madison T. Hindes, Anthony M. McElligott, Giles Best, et al.
Cancer Letters (2025), pp. 217441-217441
Closed Access
Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region
Mohamed A. Yassin, Khalil Al Farsi, Anas Hamad, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Mohamed A. Yassin, Khalil Al Farsi, Anas Hamad, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
X. Wang, Mei Jia
The Kaohsiung Journal of Medical Sciences (2025)
Open Access
Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report
Arina Martynchyk, Cameron Wellard, Eliza Chung, et al.
Internal Medicine Journal (2025)
Closed Access
Arina Martynchyk, Cameron Wellard, Eliza Chung, et al.
Internal Medicine Journal (2025)
Closed Access
Ibrutinib enhances the bias of T cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia
Fisal Tantoush, David Allsup, Leigh Naylor‐Adamson, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Fisal Tantoush, David Allsup, Leigh Naylor‐Adamson, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping
Emile Niyonizeye, Xiaoqian Wang, Dongyao Yan, et al.
Annals of Hematology (2025)
Open Access
Emile Niyonizeye, Xiaoqian Wang, Dongyao Yan, et al.
Annals of Hematology (2025)
Open Access
Screening and identification analysis of core markers for leukemia and cervical cancer: Calmodulin 3 as a core target
Danfeng Shao, Huaiying Yu, Xiaoqing Zhu
Medicine (2025) Vol. 104, Iss. 14, pp. e41665-e41665
Open Access
Danfeng Shao, Huaiying Yu, Xiaoqing Zhu
Medicine (2025) Vol. 104, Iss. 14, pp. e41665-e41665
Open Access
The global burden of childhood and adolescent leukaemia and attributable risk factors: An analysis of the Global Burden of Disease Study 2019
Yiran Cui, Yan Yan
Journal of Global Health (2024) Vol. 14
Open Access | Times Cited: 3
Yiran Cui, Yan Yan
Journal of Global Health (2024) Vol. 14
Open Access | Times Cited: 3
Revolutionizing chronic lymphocytic leukemia diagnosis: A deep dive into the diverse applications of machine learning
Mohamed Elhadary, Amgad M. Elshoeibi, Ahmed Badr, et al.
Blood Reviews (2023) Vol. 62, pp. 101134-101134
Open Access | Times Cited: 8
Mohamed Elhadary, Amgad M. Elshoeibi, Ahmed Badr, et al.
Blood Reviews (2023) Vol. 62, pp. 101134-101134
Open Access | Times Cited: 8
HLA Gene Polymorphisms in Romanian Patients with Chronic Lymphocytic Leukemia
Maria Tizu, Bogdan Calenic, Mihai Hârza, et al.
Genetics Research (2024) Vol. 2024, pp. 1-9
Open Access | Times Cited: 2
Maria Tizu, Bogdan Calenic, Mihai Hârza, et al.
Genetics Research (2024) Vol. 2024, pp. 1-9
Open Access | Times Cited: 2
Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia
Samir Mouhssine, Nawar Maher, Sreekar Kogila, et al.
Hematology Reports (2024) Vol. 16, Iss. 2, pp. 270-282
Open Access | Times Cited: 2
Samir Mouhssine, Nawar Maher, Sreekar Kogila, et al.
Hematology Reports (2024) Vol. 16, Iss. 2, pp. 270-282
Open Access | Times Cited: 2
Global, regional, and national burdens of leukemia from 1990 to 2019: A systematic analysis of the global burden of disease in 2019 based on the APC model
Xiang Qu, Anjie Zheng, Jie Yang, et al.
Cancer Medicine (2024) Vol. 13, Iss. 17
Open Access | Times Cited: 2
Xiang Qu, Anjie Zheng, Jie Yang, et al.
Cancer Medicine (2024) Vol. 13, Iss. 17
Open Access | Times Cited: 2
Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia
Naveen Hegde, Ankit Kumar, Shaweta Kaundal, et al.
Annals of Hematology (2023) Vol. 102, Iss. 11, pp. 3125-3132
Closed Access | Times Cited: 6
Naveen Hegde, Ankit Kumar, Shaweta Kaundal, et al.
Annals of Hematology (2023) Vol. 102, Iss. 11, pp. 3125-3132
Closed Access | Times Cited: 6
Global burden of leukemia attributable to occupational exposure to formaldehyde from 1990 to 2019
Ying Xu, Yuqi Liu, Hongyu Sun, et al.
Environmental Science and Pollution Research (2023) Vol. 31, Iss. 3, pp. 3560-3571
Closed Access | Times Cited: 4
Ying Xu, Yuqi Liu, Hongyu Sun, et al.
Environmental Science and Pollution Research (2023) Vol. 31, Iss. 3, pp. 3560-3571
Closed Access | Times Cited: 4
Approved and emerging Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia
Alycia Hatashima, Mehdi Karami, Mazyar Shadman
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 13, pp. 1545-1557
Closed Access | Times Cited: 7
Alycia Hatashima, Mehdi Karami, Mazyar Shadman
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 13, pp. 1545-1557
Closed Access | Times Cited: 7
Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia
Manabu Hayama, John C. Riches
OncoTargets and Therapy (2024) Vol. Volume 17, pp. 181-198
Open Access | Times Cited: 1
Manabu Hayama, John C. Riches
OncoTargets and Therapy (2024) Vol. Volume 17, pp. 181-198
Open Access | Times Cited: 1
Temporal changes in the burden of leukaemia and lymphoma in the Australasia and Oceania regions, 2010–2019: an analysis of the Global Burden of Disease Study 2019
Thi Quynh Anh Ho, Peter Lee, Lan Gao
BMJ Open (2024) Vol. 14, Iss. 11, pp. e084943-e084943
Open Access | Times Cited: 1
Thi Quynh Anh Ho, Peter Lee, Lan Gao
BMJ Open (2024) Vol. 14, Iss. 11, pp. e084943-e084943
Open Access | Times Cited: 1
Inhibitory Potential of the Ocimum sanctum Phytochemicals on Bruton’s Tyrosine Kinase, a Well-Known Drug Target for Treatment of Chronic Lymphocytic Leukemia: An In Silico Investigation
Shabir Ahmad Mir, Yahya Madkhali, Ahmad Firoz, et al.
Molecules (2023) Vol. 28, Iss. 8, pp. 3287-3287
Open Access | Times Cited: 3
Shabir Ahmad Mir, Yahya Madkhali, Ahmad Firoz, et al.
Molecules (2023) Vol. 28, Iss. 8, pp. 3287-3287
Open Access | Times Cited: 3
Preservation of fertility in female patients with hematologic diseases
Marika Bini Antunes, Sara Pinto Cardeal, Manuel Ferreira‐Magalhães, et al.
Blood Reviews (2023) Vol. 62, pp. 101115-101115
Closed Access | Times Cited: 3
Marika Bini Antunes, Sara Pinto Cardeal, Manuel Ferreira‐Magalhães, et al.
Blood Reviews (2023) Vol. 62, pp. 101115-101115
Closed Access | Times Cited: 3
Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India
Prerika Nehra, Akashdeep Singh Chauhan, Pankaj Malhotra, et al.
The Lancet Regional Health - Southeast Asia (2023) Vol. 13, pp. 100201-100201
Open Access | Times Cited: 2
Prerika Nehra, Akashdeep Singh Chauhan, Pankaj Malhotra, et al.
The Lancet Regional Health - Southeast Asia (2023) Vol. 13, pp. 100201-100201
Open Access | Times Cited: 2
